January 21, 2021
Business News

Exicure, Inc. Reports Third Quarter 2020 Financial Results and Corporate Progress


CHICAGO & CAMBRIDGE, Mass.–()–Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the quarter and nine months ended September 30, 2020 and provided an update on corporate progress.

“Exicure has seen growth and clinical and pre-clinical advancement during the third quarter of this year,” said Dr. David Giljohann, Exicure’s Chief Executive Officer. “During the third quarter of 2020, Exicure hosted a virtual KOL event where we presented promising interim results from our ongoing Phase 1b/2 clinical trial of cavrotolimod (AST-008) and we announced that our poster on the safety and…



Click here to view the original article.

Related Posts

You might also like ...

Guidehouse Insights Report Shows Global Revenue for Lighting-Based Real-Time Location Systems for the Healthcare Industry Is Expected to Reach $1B by 2030
Sapreme Appoints Henrik Luessen as Chief Business Officer
Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases